Por: MarketWatch Business August 08, 2023
The positive results represent the first concrete evidence that the new class of weight-loss drugs from Novo Nordisk (ticker: NVO) and Eli Lilly (LLY) offer substantive health benefits beyond weight reduction for overweight or obese patients without diabetes. The results will vastly increase pressure on insurers to pay for Novo Nordisk’s Wegovy, as well as other similar weight-loss treatments. It could boost support for federal legislation to... + full article
Forbes USA Business March 14, 2023
Topline Pharmaceutical heavyweight Novo Nordisk on Tuesday it is cutting prices for several insulin drugs in the U.S., following a similar move from drugmaker Eli Lilly as healthcare companies come under increasing pressure to lower prices for the lifesaving diabetes medication.... + más
Novo Nordisk to lower insulin prices by 75% | Fox Business
Novo Nordisk to slash U.S. insulin prices by up to 75%, following move by Eli Lilly | CNBC
Forbes USA Tech January 25, 2023
Since its launch in 2021, Novo Nordisk’s weight loss drug, Wegovy, set the stage for the next ... [+] generation of anti-obesity drugs. Now a new drug on the scene promises to be more effective and safer than any other weight loss drug before.getty Obesity remains one of the... + más
New guidance: Use drugs, surgery early for obesity in kids | ABC News
Use drugs and surgery early for obesity in kids, new guidance says | Orlando Sentinel
Portland Press Herald USA Health January 09, 2023
Children struggling with obesity should be evaluated and treated early and aggressively, including with medications for kids as young as 12 and surgery for those as young as 13, according to new guidelines released Monday. The longstanding practice of “watchful waiting,” or... + más
Forbes USA Business December 21, 2022
With economic worries unsettling investors, it is not surprising that leading advisors, and contributors to , are looking to the pharmaceutical sector – a group typically prized for its recession resistance and supported by long-term demographics. Here’s a look at seven... + más
The Most-Bought Guru Stocks Of The 3rd Quarter | Forbes
FDA approves controversial new drug designed to slow the progression of ALS | CNBC
Forbes USA Business December 15, 2022
Along the corridors of Indianapolis-based Eli Lilly, NBP may not have the brand swagger of Trulicity or Mounjaro, but as the drugmaker eyes a rich menu of growth opportunities, the sturdy acronym promises to be a powerful pain reliever. Or so Lilly CFO Anat Ashkenazi explains,... + más
Twitter was once a necessity for major brands. Under Elon Musk, it's now high risk. | CBS News
A fake tweet sparked panic at Eli Lilly and may have cost Twitter millions | Portland Press Herald
MarketWatch USA Business October 02, 2022
For the roughly 42% of Americans who are obese, these results are nothing short of a miracle. Wall Street is thrilled, predicting a global market for the drugs as big as by 2030. And physicians feel they finally have a new treatment option for their patients. “I was... + más
‘There's no way that patients are going to be able to afford that.’ Why aren’t new drugs that can help you lose weight more widely used? | MarketWatch
TikTok pulls posts for weight loss drugs that reached kids | The Verge
MarketWatch USA Politics October 02, 2022
About iurex | Privacy Policy | Disclaimer |